Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial☆

ESMO Open · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles